UK Receives £1bn Confidence Boost From Industry Investment In Life Sciences Sector
The international biopharma industry is backing the UK life sciences sector, with UCB spearheading the charge with a £1bn commitment to R&D in the nation still in a state of flux regarding its exit from the European Union in 2019.
You may also be interested in...
Japan is aiming for the betterment of pharma R&D and medical services for rare disease patients by building a database connecting genome analysis data and clinical records. While several clinical studies are planned for the next couple of years, there are also concerns around the actual trickle-down of benefits to patients and data privacy.
The pharma, biotech and allied industries came together to celebrate another year of excellence at the 14th Annual Scrip awards in London on Nov. 28, hosted by the Right Honourable Lord (William) Hague.
MSD's R&D head Roger Perlmutter and Sir John Bell tell Scrip the UK government needs to offer better manufacturing incentives to the life science sector and also encourage more efficient drug innovation there.